Daiichi Sankyo expands scope of ArQule oncology alliance
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has widened the scope of its 2008 alliance with ArQule for the discovery of novel kinase-inhibiting oncology drugs to include a third therapeutic target, with an option for a fourth.